OssDsign (OSSD) Q3 2026 earnings summary

Executive summary

• Q3 net sales were SEK 35.7m, down 18.8% YoY reported; stronger summer holidays weighed on demand, while sales improved through the quarter.

• Growth plans center on Catalyst awareness, commercial reorganization and clinical evidence; US sales leadership roles were filled.

Financial highlights

• Q3 sales were SEK 35.7m vs SEK 44.0m a year earlier, down 18.8% reported and 19.8% in constant currency.

• Q3 adjusted EBIT was SEK -6.6m vs -5.3m YoY; reported EBIT was SEK -6.9m vs -5.5m.

• Q3 net loss was SEK 5.8m, broadly unchanged YoY; EPS was SEK -0.1.

• 9M sales were SEK 110.4m, down 13.6% at constant FX and 18.3% reported; adjusted EBIT was SEK -32.0m vs -17.1m.

• 9M net loss was SEK 28.7m, broadly unchanged YoY; EPS was SEK -0.3.

Outlook and guidance

• Strategy remains focused on restoring growth through Catalyst awareness and a stronger US commercial channel; commercial reorganization is expected to support momentum later than initially planned.

• MIS Catalyst and Catalyst Strip development continued; a Catalyst labeling-change submission was made in Q3.

• Next PROPEL registry data release is expected in Q1 2027; timing for the first patient in the planned level one study is forthcoming.